Micronized Clobetasol Propionate highlights how particle engineering can support improved dermal delivery while maintaining formulation control. By reducing particle size, micronization may enhance skin penetration, enabling the API to act closer to sites associated with inflammation, redness, and scaling.
At the molecular level, Clobetasol Propionate is understood to interact with glucocorticoid receptors, contributing to the modulation of inflammatory pathways involved in plaque psoriasis. When developed and used appropriately, this supports effective short-term symptom management under medical supervision.
Micronized formats also offer flexibility at the formulation stage. Lighter creams, foams, and advanced topical systems can improve patient acceptability and adherence, while helping formulators balance potency with controlled exposure.
At Avik Pharmaceutical Ltd., we focus on manufacturing highly potent APIs that are engineered for formulation performance, regulatory compliance, and consistency across batches. Our micronized Clobetasol Propionate is developed to support dermatology innovators in building effective,patient-centric topical therapies.
